Parallax Diagnostics Announces Intent to Develop a Rapid Screening Test for COVID-19 on its Patented FDA 510(K) Approved Diagnostic Platform
11. März 2020 07:00 ET
|
Parallax Health Sciences, Inc.
Company will Partner to Accelerate The Deployment of Diagnostic Solutions Under Patent Protected Service Areas Including China, Hong Kong, India, and US NEW YORK, NY, March 11, 2020 (GLOBE...